Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 1/20 | 0.59 |
| ▸ | PIM1 | P11309 | 1/20 | 0.59 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.59 |
| ▸ | PARP1 | P09874 | 7/20 | 0.40 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.40 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 3/20 | 0.39 |
| ▸ | F2 | P00734 | 2/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.35 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.35 |
| ▸ | F9 | P00740 | 1/20 | 0.35 |
| ▸ | AOC2 | O75106 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16720474 | 0.89 | ROCK2 (0.55) | ROCK2PIM1PIM3PARP1PARP15 | |
| SCHEMBL16719754 | 0.89 | ROCK2 (0.46) | ROCK2PIM1PIM3HPGDPLA2G10 | |
| SCHEMBL16720607 | 0.86 | ROCK2 (0.43) | ROCK2PIM1PIM3SMOF10 | |
| SCHEMBL694187 | 0.85 | ROCK2 (0.46) | ROCK2PIM1PIM3PARP15PARP10 | |
| Hydrochloric Acid SCHEMBL10637882 | 0.81 | ROCK2 (0.66) | ROCK2PIM1PIM3PARP1PARP15 | |
| SCHEMBL16719724 | 0.80 | FGFR1 (0.40) | ROCK2PIM1PIM3HPGDFGFR1 | |
| SCHEMBL4280060 | 0.80 | ROCK2 (0.53) | ROCK2PIM1PIM3HPGDFGFR1 | |
| SCHEMBL695230 | 0.78 | ROCK2 (0.41) | ROCK2PIM1PIM3F10HPGD | |
| SCHEMBL16720418 | 0.77 | ROCK2 (0.42) | ROCK2PIM1PIM3FGFR1 | |
| SCHEMBL16720346 | 0.77 | HPGDS (0.39) | ROCK2PIM1PIM3HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE KA RECHERCHE MÉDICALE (FR) | 2018-09-18 | — | — | US | claimed |
| EP-2421825-B9 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-20 | — | — | EP | claimed |
| EP-2421825-B1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-01-01 | — | — | EP | claimed |
| US-8455476-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2013-06-04 | — | — | US | claimed |
| US-8362001-B2 | Azetidinyl diamides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-29 | — | — | US | claimed |
| EP-2421848-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| EP-2421825-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | claimed |
| US-20100331300-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-30 | — | — | US | claimed |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | claimed |
| WO-2010124119-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| WO-2010124108-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | claimed |
| US-20190216804-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-07-18 | — | — | US | disclosed |
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE KA RECHERCHE MÉDICALE (FR) | 2018-09-18 | — | — | US | disclosed |
| US-20170239242-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | UNIVERSITÉ PARIS CITÉ (FR) | 2017-08-24 | — | — | US | disclosed |
| EP-3197450-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-08-02 | — | — | EP | disclosed |
| EP-2421848-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | Janssen Pharmaceutica N.V. (BE) | 2012-02-29 | — | — | EP | disclosed |
| US-20100331300-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-30 | — | — | US | disclosed |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-23 | — | — | US | disclosed |
| WO-2010124119-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
| WO-2010124108-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10076517-B2 | Methods and pharmaceutical compositions for the treatment of fibrosis | LIPA, MGLL, PNLIP | ROCK2 1022/4885PIM1 2622/4885PIM3 2786/4885 |
| US-20170239242-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | LIPA, MGLL, PNLIP | ROCK2 1022/4885PIM1 2622/4885PIM3 2786/4885 |
| US-20190216804-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF FIBROSIS | MGLL, LIPA, PNLIP | ROCK2 1083/4885PIM1 2751/4885PIM3 2924/4885 |
| US-20100331300-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | ROCK2 2396/4885PIM1 4048/4885PIM3 4240/4885 |
| US-20100324014-A1 | AZETIDINYL DIAMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | PNLIP, LPL, LIPA | ROCK2 2396/4885PIM1 4048/4885PIM3 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.